Literature DB >> 11815585

Differential regulation of L1 and L2 beta-lactamase expression in Stenotrophomonas maltophilia.

Matthew B Avison1, Catherine S Higgins, Peter J Ford, Charlotte J von Heldreich, Timothy R Walsh, Peter M Bennett.   

Abstract

It has been reported that Stenotrophomonas maltophilia L1 and L2 beta-lactamase expression is coordinated. We have isolated S. maltophilia mutants where (i) L1 is constitutively hyper-expressed and L2 is inducible; (ii) L2 is hyper-expressed and L1 is inducible; and (iii) L1 and L2 are constitutively hyper-expressed. The frequency of isolating type 1 and 2 mutants is c. 10(-7), indicating that promoter mutations are probably not involved and providing strong evidence that L1 and L2 expression is not, after all, coordinated. The frequency of isolating type 3 mutants is c. 10(-9), however, implying that there is a significant overlap between the regulatory mechanisms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11815585     DOI: 10.1093/jac/49.2.387

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  22 in total

1.  Isolation of multidrug-resistant Stenotrophomonas maltophilia from cultured yellowtail (Seriola quinqueradiata) from a marine fish farm.

Authors:  Manabu Furushita; Akira Okamoto; Toshimichi Maeda; Michio Ohta; Tsuneo Shiba
Journal:  Appl Environ Microbiol       Date:  2005-09       Impact factor: 4.792

2.  Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.

Authors:  Aki Okazaki; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

3.  Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.

Authors:  Rouh-Mei Hu; Kuang-Jay Huang; Lii-Tzu Wu; Ying-Ju Hsiao; Tsuey-Ching Yang
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

4.  Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator.

Authors:  Aki Okazaki; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

Review 5.  Stenotrophomonas maltophilia: Significant contemporary hospital pathogen - review.

Authors:  O Nyc; J Matejková
Journal:  Folia Microbiol (Praha)       Date:  2010-06-06       Impact factor: 2.099

Review 6.  Epidemiology of β-Lactamase-Producing Pathogens.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

7.  Activity of colistin in combination with tigecycline or rifampicin against multidrug-resistant Stenotrophomonas maltophilia.

Authors:  J W Betts; L M Phee; N Woodford; D W Wareham
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-04-30       Impact factor: 3.267

Review 8.  Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

9.  Sideromimic Modification of Lactivicin Dramatically Increases Potency against Extensively Drug-Resistant Stenotrophomonas maltophilia Clinical Isolates.

Authors:  Karina Calvopiña; Klaus-Daniel Umland; Anna M Rydzik; Philip Hinchliffe; Jürgen Brem; James Spencer; Christopher J Schofield; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

10.  Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes.

Authors:  Mark A Toleman; Peter M Bennett; David M C Bennett; Ronald N Jones; Timothy R Walsh
Journal:  Emerg Infect Dis       Date:  2007-04       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.